A B S T R A C T The diabetogenic activity of streptozotocin has been correlated with a reduction in pyridine nucleotide synthesis in the mouse pancreatic islet. To determine the specificity of this reduction for diabetogenicity, a comparative study of streptozotocin, its cytotoxic moiety, 1-methyl-1-nitrosourea, and alloxan was performed. Streptozotocin administered intraperitoneally (i.p.) producd a dose-related reduction in islet NAD which was proportional to the degree of diabetogenicity. A diabetogenic dose, 200 mg/kg, attained a peak plasma N-nitroso intact streptozotocin concentration of 0.224 F'mol/ml and reduced the mean islet NAD from a control of 0.78 to 0.15 pmol. At borderline, 150 mg/kg, and nondiabetogenic, 100 mg/kg, doses, plasma concentrations reached 0.161 and 0.136 pmol/ml, and NAD was 0.36 and 0.86 pmol/islet, respectively. 1-Methyl-1-nitrosourea, 100 mg/kg, attained a maximum N-nitroso intact 1-methyl-1-nitrosourea concentration of 0.162 /mol/ ml and reduced the mean NAD to 0.58 pmol/islet, and was nondiabetogenic; 200 mg/kg attained a peak plasma concentration of 0.344 /mol/ml and depressed NAD to 0.38 pmol/islet, and was inconsistently diabetogenic. Islet NAD of 0.4 pmol/islet or greater is required for integrity of the beta cell. A diabetogenic dose of alloxan, 500 mg/kg, did not depress NAD, 0.85 pmol/islet, therefore confirming that its mechanism of diabetogenicity differs from that of streptozotocin.
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In vivo uptake of [methyl-"4C]streptozotocin by islets was 3.8 times that of [methyl-14C]-1-methyl-1-nitrosourea, whereas uptake by the exocrine pancreas favored 1-methyl-1-nitrosourea over streptozotocin 2.4:1. The decreased islet uptake of 1-methyl-1-nitrosourea correlates with the 3.5 times increased molar dosage required to produce islet NAD depression comparable to that of 3treptozotocin, 150 mg/kg. These studies indicate that INTRODUCTION Streptozotocin, composed of the cytotoxic moiety, 1-methyl-l-nitrosourea (MNU)' attached to the carbon-2 position of glucose, is an antibiotic isolated from cultures of Streptomyces achromogenes (1) . This compound produces diabetes in laboratory animals through the destruction of the pancreatic beta cell (2) and has demonstrable clinical antitumor activity against pancreatic islet-cell carcinoma (3). The diabetogenicity of streptozotocin has been correlated with a rapid reduction in pancreatic islet pyridine nucleotide concentration and subsequent beta cell necrosis (2, 4) . Nicotinamide, but not nicotinic acid, acts as a specific inhibitor of streptozotocin-induced diabetes by preventing the reduction of NAD (2) . While both streptozotocin and its cytotoxic moiety, MNU, decrease hepatic NAD concentrations, MNU was previously considered to be nondiabetogenic (5, 6) . Alloxan also produces experimental diabetes through the destruction of the pancreatic beta cell (7) and has demonstrated limited clinical antitumor activity against malignant insulinoma (8) .
Because the end result of alloxan and streptozotocin treatment is qualitatively similar, the present study was undertaken to determine whether the two agents had a common mechanism of diabetogenic action at the biochemical level. In this study, we compare the NAD content of individual mouse pancreatic islets after in vivo treatment with diabetogenic doses of streptozo-tocim or alloxan, or after a lethal dose (LD) of MNU, to determine the specificity of the reduction of NAD for the diabetogenicity of streptozotocin.
METHODS
Male Swiss mice, weighing 18-25 g, maintained on a standard laboratory diet (Ralston Purina Co., St. Louis, Mo.) and water ad libitum, were used throughout. All drugs were dissolved immediately before use: streptozotocin (glucopyranose, 2-deoxy-2-[3-methyl-3-nitrosoureido]) (lot no. 2465-EHL-86, The Upjohn Co., Kalamazoo, Mich.) was prepared in 0.005 M citrate buffer, pH 4.5; MNU (NSC 23909) and alloxan (NSC 7169) were prepared in 0.85% sodium chloride solution (Fig. 1) . All drugs were administered intraperitoneally in a volume of 0.1 ml/10 g body weight. Controls received appropriate volumes of citrate buffer.
After the administration of each drug to a group of five mice feeding ad libitum, serial blood glucose determinations were performed as follows: 40 usl of tail vein blood were drawn into heparinized microhematocrit tubes (Sherwood Medical Industries, Inc., St. Louis, Mo.) and centrifuged for 3 min in an International model MB hematocrit centrifuge (Arthur H. Thomas Co., Philadelphia, Pa.). A 10-,ul aliquot of the plasma supernate was then assayed for glucose by the method of Kingsley and Getchell (9) .
Isolation of individual pancreatic islets was performed by a method previously described (4) . In brief, 3 h after drug administration, the six animals in each group were sacrificed and the pancreatic duct and parenchyma injected with 1% collagenase (Worthington Biochemical Corp., Freehold, N. J.) in Hank's balanced salt solution (HBSS) before removal. The pancreatica of each group were combined, minced, and agitated in 1% collagenase in HBSS at 370C for 10 min, then washed five times with HBSS at 40C. By using a dissecting microscope, islets were serially transferred in HBSS until free of contaminating exocrine tissue. Individual islets, suspended in 5 ,ul of HBSS, were transferred into 1.5-ml Eppendorf microtubes (Matheson Scientific Div, Will Ross Inc., Elk Grove Village, Ill.) and ruptured with 5 ,ul of 0.1 N HCl followed by six cycles of freeze-thawing. 5-Al aliquots of the final HBSS rinse served as blanks for each group. All samples were frozen and lyophilized.
The NAD content of each individual islet or HBSS blank was measured by using a radiometric cycling assay as shown in Fig. 2 . 25 mCi of tritiated ethanol, sp act 25 mCi/ mmol, (New England Nuclear, Boston, Mass.) were further purified by adding 1 ml of distilled water and sublimating twice. The product, containing only 0.0016% nonvolatile impurities, was then diluted to 20 ml with distilled water and frozen in 1-ml aliquots. Yeast alcohol dehydrogenase (ADH), sp act 200 U/mg, and rabbit muscle 15 ,000 g for 1Z min. The enzymes were subsequently recrystallized with ammonium sulfate at 40C. This purification procedure was repeated and the final enzyme preparations stored at 40C in a volume of final crystallization liquid equal to the original volume of each enzyme. Aliquots of these enzyme preparations were dissolved in a 10-fold volume of 0.1 M pyrophosphate buffer, pH 9.5 (Sigma Chemical Co.) immediately before addition to the cycling assay cocktail. Absolute ethanol, USP reagent grade, was diluted to a concentration of 0.001 M with distilled water; pyruvate (Sigma Chemical Co.) was dissolved before use in 0.1 M pyrophosphate buffer, pH 9.5, to a final concentration of 0.018 M. NAD standards (Boehringer-Mannheim Corp.), ranging in concentration from 0.19 to 1.5 pmol/5 ,l were prepared in advance in distilled water and frozen in aliquots to be thawed just before use.
The cycling assay for NAD was performed as follows. After lyophilization, samples or HBSS blanks were dissolved in 5 Al of distilled water. To each microtube was added 10 Al of cocktail containing LDH, ADH, 0.1 M pyrophosphate buffer, 0.001 M ethanol, tritiated ethanol, and 0.018 M pyruvate (5: 5: 5: 1: 1:1 by volume). In this system, the rate-limiting factor is the NAD content of the sample (10). The reaction is allowed to cycle for 15 h at 20°C; the reaction is terminated and the tritiated ethanol substrate removed by heating at 95°C for 25 min in an Eppendorf Thermostat no. 3401 micro-oven (Brinkmann of tritiated lactate proportional to the NAD content of the Instruments, Inc., Westbury, N. Y.), which leaves a residue sample, standard, or blank. 50 Al of water were added to each microtube to dissolve the tritium-labeled lactate residue. Each microtube was then transferred into a scintillation vial containing 15 ml of Aquasol (New England Nuclear) and counted by using a Packard Tri-Carb liquid scintillation spectrometer, model no. 4322 (Packard Instrument Co., Inc., Downers Grove, Ill. Plasma streptozotocin and MNU concentrations were determined by measurement of the intact N-nitroso group of the respective molecules by using the spectrophotometric method of Forist (6, 11) .
The specificity of in vivo drug uptake into the islets of Langerhans, exocrine pancreas, liver, kidney, brain, muscle, adipose tissue, and bone marrow was determined by the following procedures: 15 (Fig. 3) . Streptozotocin, 200 mg/kg, produced a transient hyperglycemic response at 1 and 3 h after intraperitoneal administration. At 9 h post-treatment, the mean blood glucose, 76 mg/100 ml, was significantly reduced from the pretreatment level (P <0.01) (17) . All streptozotocin-treated mice were demonstrated to be hyperglycemic at 48 and 72 h, with mean blood glucose concentrations of 353 mg/100 ml and 317 mg/100 ml, respectively (P < 0.01). Alloxan, 300 mg/kg, also produced a hyperglycemic phase at 1 h post-treatment, with mean blood glucose of 364 mg/100 ml, but unlike streptozotocin, the mean blood glucose had decreased to below control levels by 3 and was significantly depressed to 53 mg/100 ml by 6 h (P < 0.01). At (Fig. 4) To explain the relative ineffectiveness of MNU as a diabetogenic agent, a comparative study of drug distribution of streptozotocin and MNU was performed. To avoid possible contamination of the pancreas and other (2, 4) and is specific in its protective action against streptozotocin-induced diabetes (2, 18 (19) . They base their conclusion on the finding that intraperitoneally administered NAD only partially prevented streptozotocin-induced diabetes, as determined by histologic examination. However, there has been no demonstration that intact NAD can be taken up into islets. In addition, the work of Kaplan, Goldin, Humphreys, Ciotti, and Stolzenbach has demonstrated that intraperitoneally injected NAD is a grossly ineffective means of increasing intracellular NAD when compared with intraperitoneally injected nicotinamide (20) .
The diabetogenicity of alloxan is also mediated via pancreatic islet beta cell necrosis, although the specific mechanism of action remains controversial (7, 21, 22 (24, 25) , and alteration of splanchnic bed perfusion with reduction in the delivery of drug to the beta cell (nicotinic acid) (26) . Nicotinamide had previously been reported to protect against alloxaninduced diabetes (26) . However, recent work indicates that only when nicotinamide is administered before alloxan is the pancreatic islet protected, whereas nicotinamide administered up to 60 min after streptozotocin still has an antagonistic effect (27) . In addition, the study of Lazarus and Shapiro has shown a failure of nicotinamide to prevent beta cell destruction by alloxan in the mouse (19) . The temporal development of diabetes is similar with both alloxan and streptozotocin. The hypoglycemic phases at 3-8 and 6-9 h, respectively for the two agents, have been shown to result from a release of stored insulin, temporally related to beta cell necrosis (7, 22, 28) . For the comparative study of NAD content, the time period chosen for study, 3 h post-treatment, just precedes actual beta cell destruction. Based upon the time of onset of hypoglycemia, alloxan, at the doses employed in this study, acts at least as rapidly as streptozotocin in destroying the beta cell. Alloxan, 500 mg/kg, did not decrease pancreatic islet NAD within 3 h after injection. This is consistent with previous work that has shown that, unlike streptozotocin, diabetogenic doses of alloxan do not depress hepatic NAD concentrations (5) . The demonstration that the diabetogenicity of streptozotocin, but not alloxan, correlates with early interference of pancreatic islet pyridine nucleotide metabolism, and the failure of nicotinamide to prevent alloxan-but not streptozotocin-induced diabetes when given after the diabetogenic agents (19, 27) . strongly suggests that the mechanism of diabetogenicity is different for the two drugs.
The addition of the glucose carrier to the MNU cytotoxic moiety results in important alterations in drug distribution for specific organs. Significant differences in the uptake of MNU and streptozotocin were observed for liver, kidney, brain, and most interestingly for the purpose of these studies, the pancreas. MNU does not produce diabetes when administered at an LD of 100 mg/ kg, but will depress hepatic NAD concentrations to the same degree as streptozotocin, 200 mg/kg (5, 6) . In contrast to streptozotocin, MNU is nonpolar and lipid soluble, properties which allow passive diffusion across cell membranes (29) . Thus, measurable MNU uptake into islets, accompanied by a minor depression of pancreatic islet NAD concentration, was to be anticipated in the present study. At equimolar doses of MNU and streptozotocin, there was a 3.8 times increased uptake of [methyl-14C] streptozotocin into pancreatic islets. When MNU was administered at a supralethal dose of 200 mg/ kg, islet NAD was reduced to 0.380 pmol, a level equivalent to that produced by streptozotocin, 150 mg/kg. This represents a 3.5: 1 increase in molar dosage of MNU over streptozotocin to produce a comparable dia-betogenic activity as determined by plasma glucose concentrations and beta cell histology. It is of interest that the plasma N-nitroso intact streptozotocin concentration required for ctiabetogenic activity in mice, 0.161 Amol/ml, is equivalent to that observed with slow intravenous infusion of streptozotocin in man with therapeutic doses of 1.0-1.5 g/m2 (30) .
Although we have interpreted these biochemical-pharmacologic changes in specific reference to the beta cell, we recognize that the actual measurements were performed in the whole slet of Langerhans, which includes both alpha and delta cells as well. This can be justified in part by the recognition that the destructive changes within the islet associated with streptozotocin are confined to the beta cell (19) . The findings of the present studies support the concept that the glucose portion of the streptozotocin molecule facilitates the active transport of the MNU cytotoxic moiety into the pancreatic beta cell; the end result is a decrease in beta cell NAD leveis and subsequent necrosis.
